Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by DuBois, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DuBois, R. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 5, 691-692, May 2001
© 2001 Oxford University Press

COMMENTARY

New paradigms for cancer prevention

Raymond N. DuBois

Departments of Medicine and Cell Biology, Vanderbilt University Medical Center, The Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-2279, USA

Abbreviations: COX-2, cyclooxygenase-2; EGFR, epidermal growth factor receptor; NSAIDS, non-steroidal anti-inflammatory drugs.


   Introduction
 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been studied extensively for their ability to delay or inhibit the development of malignant and pre-malignant lesions (1). There has been a considerable amount of attention focused on this class of drugs because of previous clinical and epidemiologic studies indicating that they possess anti-neoplastic activity. Clinical observations by Waddell and Loughry first indicated that use of these agents led to regression . . . [Full Text of this Article]


   Notes
 

   References
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Biol. CellHome page
S. A. Benitah, P. F. Valeron, and J. C. Lacal
ROCK and Nuclear Factor-{kappa}B-dependent Activation of Cyclooxygenase-2 by Rho GTPases: Effects on Tumor Growth and Therapeutic Consequences
Mol. Biol. Cell, July 1, 2003; 14(7): 3041 - 3054.
[Abstract] [Full Text] [PDF]